• Collaboration with a leading provider of gene editing systems is Ionis’ latest move to expand and diversify its technology
• CRISPR-Cas gene editing is a natural extension of Ionis’ innovative approach to delivering potentially transformative therapies
• Ionis holds webcast Nov 14 at 8 p.m. Eastern Time

CARLSBAD, CALIFORNIA. and EMERYVILLE, CALIFORNIA., November 14, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. IONS and metagenomes announced today that the companies have entered into a collaboration that will leverage Ionis’ deep expertise in RNA-targeting therapeutics and Metagenomi’s versatile next-generation gene-editing systems to pursue a mix of validated and novel genetic targets that have the potential to expand therapeutic options for patients. The companies will conduct research together, initially aimed at providing investigational medicinal products for up to four genetic targets. Ionis has the right to add four more goals when previously set development milestones are reached.

“Ionis was founded over 30 years ago to discover and develop novel, highly personalized medicines using our powerful RNA targeting technology platform. This partnership with Metagenomi supports Ionis’ strategic goal of advancing our technology and expanding our capabilities to deliver precise genetic medicines. Together, we can expand the application of gene editing by leveraging Ionis’ deep expertise in nucleic acid therapeutics to optimize and expand the reach of gene editing for liver targets and new tissues,” said Ionis Chief Executive Officer Brett P. Monia, Ph.D. “This alliance brings both of our companies closer to delivering next-generation therapies that have the potential to revolutionize how diseases are treated.”

“Gene editing has the potential to transform chronic therapies into potentially curative treatments for patients who currently have limited options,” said Brian C.Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi. “This collaboration is a strategic move to bring Metagenome…